NasdaqGS - Delayed Quote USD

REGENXBIO Inc. (RGNX)

16.19 +0.13 (+0.81%)
At close: 4:00 PM EDT
16.19 0.00 (0.00%)
After hours: 4:20 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Kenneth T. Mills President, CEO & Director 1M 720.99k 1975
Mr. Vittal K. Vasista Executive VP & CFO 666.5k 573.3k 1968
Mr. Curran M. Simpson M.S. Executive VP & COO 698.6k -- 1962
Dr. Olivier Danos Ph.D. Executive VP & Chief Scientific Officer 778.85k -- 1958
Dr. Stephen Pakola M.D. Executive VP & Chief Medical Officer 674.05k -- 1969
Mr. Patrick J. Christmas II, J.D. Executive VP & Chief Legal Officer 1.11M 1.29M 1971
Ms. Shiva G. Fritsch Chief Communications & People Officer -- -- --
Dr. Laura A. Coruzzi J.D., Ph.D. Executive Vice President of Intellectual Property -- -- 1954
Dr. Ram Palanki Pharm.D. Executive VP of Commercial Strategy & Operations -- -- 1977

REGENXBIO Inc.

9804 Medical Center Drive
Rockville, MD 20850
United States
240 552 8181 https://www.regenxbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
344

Description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Corporate Governance

REGENXBIO Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 01, 2024 - May 06, 2024
REGENXBIO Inc. Earnings Call

Related Tickers

QURE uniQure N.V.
4.5300
-0.22%
 
FDMT 4D Molecular Therapeutics, Inc.
23.25
-1.19%
 
VYGR Voyager Therapeutics, Inc.
7.62
+2.70%
 
RARE Ultragenyx Pharmaceutical Inc.
44.24
+0.89%
 
LBPH Longboard Pharmaceuticals, Inc.
19.72
+2.44%
 
PMVP PMV Pharmaceuticals, Inc.
1.7500
+2.34%
 
IONS Ionis Pharmaceuticals, Inc.
41.59
-0.60%
 
PASG Passage Bio, Inc.
1.3200
+8.20%
 
SWTX SpringWorks Therapeutics, Inc.
45.53
+3.01%
 
REPL Replimune Group, Inc.
6.42
+4.39%